Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Immunomedics, Inc.    IMMU

IMMUNOMEDICS, INC. (IMMU)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Immunomedics : Leaps Despite Q1 Loss

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 09:27pm CEST
Immunomedics, Inc. (NASDAQ: IMMU) shares spiked in Friday trading on first quarter numbers Total costs and expenses for the first quarter ended September 30, 2017 were $22.3 million, compared to $15.7 million for the same quarter in fiscal 2017, an increase of approximately 42%. Net loss attributable to stockholders was $118.7 million, or approximately $0.97 per share, for the first quarter ended September 30, 2017, compared to $16.2 million, or approximately $0.17 per share, for the same quarter in fiscal 2017, an increase of approximately 633%. Cash, cash equivalents, and marketable securities totaled $139.6 million as of September 30, 2017. Chairman Behzad Aghazadeh said, “During the quarter and over the course of the year, we have made significant progress toward preparing a BLA for accelerated approval of IMMU-132, our breakthrough therapy candidate for the treatment of late-stage metastatic triple-negative breast cancer (mTNBC). "IMMU-132 has shown a remarkable response rate in patients and we remain sharply focused on bringing this promising treatment to market as soon as possible. Notably, in the quarter, we completed a number of successful meetings with the (Food and Drug Administration) including a CMC and a pre-BLA meeting, where we received positive feedback on our proposed submission plans. As such, we remain on track to meet our stated goal of submitting our BLA filing in the first quarter.” Shares gained $2.03, or 19.4%, to $12.47.

Copyright © 2017 Baystreet.ca Media Corp. All rights reserved., source Standard Equities Feed

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMMUNOMEDICS, INC.
04/19IMMUNOMEDICS INC : Notice of Delisting or Failure to Satisfy a Continued Listing..
AQ
04/10IMMUNOMEDICS INC : Entry into a Material Definitive Agreement (form 8-K)
AQ
04/09IMMUNOMEDICS : Appoints Dr. Robert Iannone Head of Research & Development and Ch..
AQ
04/02IMMUNOMEDICS INC : Submission of Matters to a Vote of Security Holders (form 8-K..
AQ
03/05Immunomedics to Present at Cowen and Company 38th Annual Health Care Conferen..
GL
02/16IMMUNOMEDICS : to Participate in RBC Capital Markets 2018 Global Healthcare Conf..
AQ
02/15Immunomedics to Participate in RBC Capital Markets 2018 Global Healthcare Con..
GL
02/12IMMUNOMEDICS : DLA Piper Advises Immunomedics on Royalty Funding and Stock Purch..
AQ
02/09IMMUNOMEDICS : reports 2Q loss
AQ
02/08IMMUNOMEDICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND R..
AQ
More news
News from SeekingAlpha
12:06aREADER INQUIRY : Is There Further Upside In Immunomedics? 
02/09Immunomedics' (IMMU) Q2 2018 Results - Earnings Call Transcript 
02/08Immunomedics beats by $0.10, misses on revenue 
01/123 THINGS IN BIOTECH YOU SHOULD LEARN : January 12, 2018 
01/12Immunomedics (IMMU) Presents At 36th Annual J.P. Morgan Healthcare Conference.. 
Financials ($)
Sales 2018 9,93 M
EBIT 2018 -124 M
Net income 2018 -159 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 275x
Capi. / Sales 2019 66,6x
Capitalization 2 735 M
Chart IMMUNOMEDICS, INC.
Duration : Period :
Immunomedics, Inc. Technical Analysis Chart | IMMU | US4529071080 | 4-Traders
Technical analysis trends IMMUNOMEDICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 22,3 $
Spread / Average Target 35%
EPS Revisions
Managers
NameTitle
Michael Pehl President & Chief Executive Officer
Behzad Aghazadeh Chairman
Michael R. Garone Chief Financial Officer & Vice President
Robert Iannone Chief Medical Officer, Head-Research & Development
David M. Goldenberg Director
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOMEDICS, INC.2.10%2 735
CELLTRION, INC.--.--%31 467
IQVIA HOLDINGS INC-0.64%20 258
LONZA GROUP-6.95%18 703
INCYTE CORPORATION-27.75%14 493
NEKTAR THERAPEUTICS44.36%13 873